-
Forbes: There Is 'A Bit' Of Hope For Sarepta Therapeutics
Friday, January 22, 2016 - 4:38pm | 209Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) were trading higher by more than 3 percent on Friday, but have lost more than 60 percent after the FDA released a briefing document related to the company's eteplirsen. Related Link: Sarepta Crashes 50% Amid Efficacy Concern Related To Eteplirsen...
-
Disappointing Drug News Sends Biogen And XOMA Shares Down
Wednesday, July 22, 2015 - 10:34am | 560Read More...Shares of Biogen Inc (NASDAQ: BIIB) were trading lower by more than 3 percent Wednesday morning after the company reported mixed results in a Phase 1 Alzheimer's study in which a 6MG dose failed to significantly slow mental decline. "We are encouraged by these new results, which...
-
How Much Does It Cost To Develop A New Drug?
Wednesday, August 14, 2013 - 9:32am | 590Read More...Don’t expect to get a direct answer from any of the big pharma firms, but in the world of big data, the answer, or something pretty close to answer, was found by doing some simple math. Last year, Forbes columnist Matthew Herper went back to the basics and simply divided each company’s spending...
